Eliminating residual iPS cells for safety in clinical application

Shigeo Masuda; Shigeru Miyagawa; Satsuki Fukushima; Nagako Sougawa; Kaori Okimoto; Chika Tada; Atsuhiro Saito; Yoshiki Sawa

doi:10.1007/s13238-015-0170-4

Protein Cell ›› 2015, Vol. 6 ›› Issue (7) : 469 -471. DOI: 10.1007/s13238-015-0170-4

NEWS AND VIEWS

Eliminating residual iPS cells for safety in clinical application

Author information +

History +

PDF (316KB)

Cite this article

Download citation ▾

Shigeo Masuda, Shigeru Miyagawa, Satsuki Fukushima, Nagako Sougawa, Kaori Okimoto, Chika Tada, Atsuhiro Saito, Yoshiki Sawa. Eliminating residual iPS cells for safety in clinical application. Protein Cell, 2015, 6(7): 469-471 DOI:10.1007/s13238-015-0170-4

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Huskey NE (2015) CDK1 inhibition targets the p53-NOXAMCL1 axis, selectively kills embryonic stem cells, and prevents teratoma formation. Stem Cell Rep4: 374-389

[2]	Masuda S (2014) Emerging innovation towards safety in the clinical application of ESCs and iPSCs. Nat Rev Cardiol11: 553-554

[3]	Tateno H (2011) Glycome diagnosis of human induced pluripotent stem cells using lectin microarray. J Biol Chem286: 20345-20353

[4]	Tateno H (2015) Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Rep.

[5]	Wu T, Pinto HB, Kamikawa YF, Donohoe ME (2015) The BET family member BRD4 interacts with OCT4 and regulates pluripotency gene expression. Stem Cell Rep4: 390-403

RIGHTS & PERMISSIONS

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.